NCI Broadens the Pool of Oncologists Enrolling Patients in Phase III Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

BETHESDA, Md-To increase the number of cancer patients participating in phase III clinical trials, the National Cancer Institute has created the Expanded Participation Project (EPP). This pilot program encourages qualified oncologists outside of the 12 NCI-sponsored Cooperative Groups to enter patients into large clinical studies organized by groups.

BETHESDA, Md—To increase the number of cancer patients participating in phase III clinical trials, the National Cancer Institute has created the Expanded Participation Project (EPP). This pilot program encourages qualified oncologists outside of the 12 NCI-sponsored Cooperative Groups to enter patients into large clinical studies organized by groups.

Under EPP, qualified oncologists can enter patients in 16 large clinical trials for breast, lung, prostate, and colorectal cancer. Other phase III trials will be opened up to EPP participating physicians later this year.

The program offers a simplified, Internet-based process for enrolling patients and a direct reimbursement of $1,500 per patient to physicians to cover their research-related time and costs.

NCI expects EPP to become a national program that will significantly reduce the time it takes to accrue the hundreds or thousands of patients necessary for phase III studies. Additional information is available on the EPP website located at http://light.emmes.com/epp

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
Related Content